Literature DB >> 17017517

The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?

S Gispert-Sanchez1, G Auburger.   

Abstract

Protein aggregates such as Lewy bodies have done much for the scientists in the field of neurodegenerative diseases: They have highlighted the affected cell populations and they have trapped the mutant disease protein. Instead of a good reputation, however, protein aggregates have received incriminations, because they are consistently seen at the site of crime. Reviewing the arguments, crucial evidence has become known that (a) the specific neuronal pathology precedes the appearance of protein aggregates in mouse models of disease, (b) the neurodegenerative disease in patients occurs with comparable severity when visible protein aggregates remain absent, (c) the neurotoxicity in vitro is best reproduced by oligomers, not polymers of the mutant disease protein. Is it feasible that protein aggregates are inert byproducts of the disease protein malconformation, or that they even represent beneficial cellular efforts to sequestrate the soluble toxic disease protein, together with normal or aberrant interactor proteins? Whatever the answer will be, one positive role of protein aggregates seems clear: In contrast to earlier speculations that random cytoplasmic proteins are trapped within the aggregates, scientists now believe that the composition of the Lewy body reflects the network of interactions between crucial players in disease pathogenesis, such as the PARK1, PARK2 and PARK5 protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017517     DOI: 10.1007/978-3-211-45295-0_18

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  9 in total

1.  Non-coding RNA as a trigger of neuropathologic disorder phenotypes in transgenic Drosophila.

Authors:  Elena Savvateeva-Popova; Andrej Popov; Abraham Grossman; Ekaterina Nikitina; Anna Medvedeva; Dmitry Molotkov; Nicholas Kamyshev; Konstantin Pyatkov; Olga Zatsepina; Natalya Schostak; Elena Zelentsova; Galina Pavlova; Dmitry Panteleev; Peter Riederer; Michail Evgen'ev
Journal:  J Neural Transm (Vienna)       Date:  2008-09-09       Impact factor: 3.575

Review 2.  Molecular chaperones and co-chaperones in Parkinson disease.

Authors:  Hemi Dimant; Darius Ebrahimi-Fakhari; Pamela J McLean
Journal:  Neuroscientist       Date:  2012-07-24       Impact factor: 7.519

Review 3.  Basic science in Parkinson's disease: its impact on clinical practice.

Authors:  Jörg B Schulz; Manfred Gerlach; Gabriele Gille; Wilfried Kuhn; Martina Müngersdorf; Peter Riederer; Martin Südmeyer; Albert Ludolph
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

4.  Nitrosative stress-induced Parkinsonian Lewy-like aggregates prevented through polyphenolic phytochemical analog intervention.

Authors:  Rituraj Pal; Manuel Miranda; Mahesh Narayan
Journal:  Biochem Biophys Res Commun       Date:  2010-12-03       Impact factor: 3.575

5.  The neuroprotective role of ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells.

Authors:  Parijat Kabiraj; Carlos A Valenzuela; Jose E Marin; David A Ramirez; Lois Mendez; Michael S Hwang; Armando Varela-Ramirez; Karine Fenelon; Mahesh Narayan; Rachid Skouta
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

Review 6.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

7.  Increased generation of cyclopentenone prostaglandins after brain ischemia and their role in aggregation of ubiquitinated proteins in neurons.

Authors:  Hao Liu; Wenjin Li; Muzamil Ahmad; Marie E Rose; Tricia M Miller; Mei Yu; Jie Chen; Jordan L Pascoe; Samuel M Poloyac; Robert W Hickey; Steven H Graham
Journal:  Neurotox Res       Date:  2013-01-25       Impact factor: 3.911

8.  The nuclear factor kappaB-activator gene PLEKHG5 is mutated in a form of autosomal recessive lower motor neuron disease with childhood onset.

Authors:  Isabelle Maystadt; René Rezsöhazy; Martine Barkats; Sandra Duque; Pascal Vannuffel; Sophie Remacle; Barbara Lambert; Mustapha Najimi; Etienne Sokal; Arnold Munnich; Louis Viollet; Christine Verellen-Dumoulin
Journal:  Am J Hum Genet       Date:  2007-05-16       Impact factor: 11.025

9.  Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease.

Authors:  Verena Kallhoff; Erica Peethumnongsin; Hui Zheng
Journal:  Mol Neurodegener       Date:  2007-03-16       Impact factor: 14.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.